• OUR STATEMENT ON COVID-19
    Anebulo Pharmaceuticals, Inc. Anebulo Pharmaceuticals, Inc.Anebulo Pharmaceuticals, Inc. Anebulo Pharmaceuticals, Inc.
    • About Us
    • Pipeline
    • Therapeutic focus
    • Contact us
    • Investors
    Open

    Press Releases

    Investors

    Investors

    • Overview
    • News & Events
      • Overview
      • Press Releases
      • IR Calendar
      • Videos
      • Email Alerts
    • Company Info
      • Overview
      • Management Team
      • Presentations
      • Contacts
      • FAQ
    • Financial Info
      • Overview
      • Financial Results
      • Income Statement
      • Balance Sheet
      • Cash Flow
    • Stock Data
      • Quote
      • Charts
      • Historical Data
      • Analyst Coverage
    • SEC Filings
      • Overview
      • All SEC Filings
      • Annual Reports
      • Quarterly Reports
      • Section 16 Filings
    • Governance
      • Overview
      • Board of Directors
      • Board Committees
      • Governance Documents
      • Board Diversity Matrix
    • News & Events

    • Overview
    • Press Releases
    • IR Calendar
    • Videos
    • Email Alerts
    Nov 14, 2023 4:05pm EST

    Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2024 Financial Results and Recent Updates

    Oct 06, 2023 4:06pm EDT

    Anebulo Pharmaceuticals Announces New CEO

    Oct 06, 2023 4:06pm EDT

    Anebulo Pharmaceuticals Announces Appointment of Bimal Shah to its Board of Directors

    Sep 20, 2023 4:29pm EDT

    Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Recent Updates

    Aug 30, 2023 8:00am EDT

    Anebulo Pharmaceuticals to Present at Upcoming Investor and Scientific Conferences

    Aug 21, 2023 8:00am EDT

    Anebulo Receives Positive Feedback from FDA on Path to Advance Phase 3 Clinical Development of ANEB-001 and Completes Dosing of Phase 2 Extension

    May 11, 2023 8:00am EDT

    Anebulo Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Recent Updates

    Mar 28, 2023 8:00am EDT

    Anebulo Pharmaceuticals Announces Positive Complete Phase 2 Clinical Data Demonstrating Potential of ANEB-001 as a Treatment for Acute Cannabinoid Intoxication

    Mar 08, 2023 8:00am EST

    Anebulo Pharmaceuticals Expands its Integrated and Outsourced Solutions

    Feb 10, 2023 8:38am EST

    Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2023 Financial Results and Recent Updates

    • 1
    • 2
    • 3
    • 4
    • arrow_forward
    rss_feed News RSS
    • Email Alerts
    • Contacts
    • RSS News Feed

    Contact

    Anebulo Pharmaceuticals
    1017 Ranch Road 620 South
    Suite 107
    Lakeway, TX 78734
    Phone: 512-598-0931
    Email: info@anebulo.com

    About

    Our Mission
    Management Team
    Board of Directors

    Pipeline

    • ANEB-001
    Anebulo Pharmaceuticals, Inc.
    Facebook Twitter Instagram Reddit
    Back to top

    ©2023 Anebulo Pharmaceuticals. All Rights Reserved.

    Privacy Policy | Terms of Use